Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com
Research analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a research report issued to clients and investors on Wednesday. The brokerage set a “buy” rating on the biotechnology company’s stock. Separately, Barclays dropped their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” […]
Research analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a research report issued to clients and investors on Wednesday. The brokerage set a “buy” rating on the biotechnology company’s stock. Separately, Barclays dropped their price target on shares of Cellectis from $7.00 to $5.00 and set an “overweight” […]
